Burns: Where are we standing with propranolol, oxandrolone, recombinant human growth hormone, and the new incretin analogs?

Gerd G. Gauglitz, Felicia N. Williams, David N. Herndon, Marc G. Jeschke

Research output: Contribution to journalArticle

40 Scopus citations

Abstract

Purpose of Review: The hypermetabolic response in critically ill patients is characterized by hyperdynamic circulatory, physiologic, catabolic and immune system responses. Failure to satisfy overwhelming energy and protein requirements after, and during critical illness, results in multiorgan dysfunction, increased susceptibility to infection, and death. Attenuation of the hypermetabolic response by various pharmacologic modalities is emerging as an essential component of the management of severe burn patients. This review focuses on the more recent advances in therapeutic strategies to attenuate the hypermetabolic response and its associated insulin resistance postburn. Recent Findings: At present, beta-adrenergic blockade with propranolol represents probably the most efficacious anticatabolic therapy in the treatment of burns. Other pharmacological strategies include growth hormone, insulin-like growth factor, oxandrolone and intensive insulin therapy. Summary: Novel approaches to the management of critical illness by judicious glucose control and the use of pharmacologic modulators to the hypercatabolic response to critical illness have emerged. Investigation of alternative strategies, including the use of metformin, glucagon-like-peptide-1 and the PPAR-γ agonists are under current investigation.

Original languageEnglish (US)
Pages (from-to)176-181
Number of pages6
JournalCurrent Opinion in Clinical Nutrition and Metabolic Care
Volume14
Issue number2
DOIs
StatePublished - Mar 2011

Keywords

  • critical illness
  • glucose
  • nutrition
  • propranolol

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Fingerprint Dive into the research topics of 'Burns: Where are we standing with propranolol, oxandrolone, recombinant human growth hormone, and the new incretin analogs?'. Together they form a unique fingerprint.

  • Cite this